AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, AutologousTransplantation, HomologousHematopoietic Stem Cell MobilizationTransplantation ConditioningStem Cell TransplantationHematologic NeoplasmsGraft vs Host DiseaseLeukapheresisGranulocyte Colony-Stimulating FactorMelphalanAntigens, CD34Blood Component RemovalCombined Modality TherapyGraft SurvivalBone Marrow TransplantationCyclophosphamideTreatment OutcomeHematopoietic Stem CellsBusulfanMultiple MyelomaMyeloablative AgonistsAntineoplastic Combined Chemotherapy ProtocolsStem CellsCord Blood Stem Cell TransplantationTransplantation ChimeraRecurrenceTissue DonorsRemission InductionAntineoplastic Agents, AlkylatingLymphoma, Non-HodgkinEtoposideSurvival RateDisease-Free SurvivalHistocompatibilityPOEMS SyndromeThiotepaWhole-Body IrradiationHistocompatibility TestingRetrospective StudiesInfectionTransplantation, IsogeneicImmunosuppressive AgentsSurvival AnalysisVidarabineAmyloidosisHematopoiesisSalvage TherapyLeukemiaIfosfamideVincristineCarmustineTime FactorsBlood CellsGraft vs Leukemia EffectCytarabineHodgkin DiseaseLeukemia, Myeloid, AcutePlatelet CountMyelodysplastic SyndromesCytomegalovirus InfectionsAnemia, AplasticBlood Cell CountLymphomaLiver TransplantationCytophagocytosisLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplasmsFollow-Up StudiesLymphocyte DepletionFatal OutcomeFeasibility StudiesLivedo ReticularisHistiocytosis, Non-Langerhans-CellDoxorubicinOpportunistic InfectionsHematologic DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaCyclosporineHLA AntigensBone MarrowBlood DonorsImmunophenotypingProspective StudiesImmunosuppressionRecombinant ProteinsMesenchymal Stem Cell TransplantationPrednisoneLymphoma, T-CellBone Marrow PurgingPilot ProjectsPrognosisCarboplatinAntineoplastic AgentsBone Marrow DiseasesAntigens, CDKidney TransplantationNeoplasm, ResidualBlood Group Incompatibility
Autologous peripheral bloodOverall survivalPatientsHSCTLymphomaTransplantKidney TransplantationPost-transplantationMultiple myelomaGraft-versus-RemissionDonorsLymphomasPrognosticHigh-doseLymphocytesMedianOutcomesHaematopoietic stem cellsProgression-free surRegimenGranulocyte colonyMarrow TransplantationDiseaseCountsCordOutcomeTreatmentNeoplasmThrombocytopeniaClinicalDifferentiationASCTOncologyDonorEndothelial progenitor cellsMethodsCurativeEngraftmentMalignantMyelodysplastic syndromeMononuclear2022ConditioningProgenitor cell
Autologous peripheral blood6
Overall survival14
  • The 5-year event-free survival and overall survival were 91.4% (95% confidence interval, 89.6%-93.3%) and 92.9% (95% confidence interval, 91.1%-94.6%), respectively. (duke.edu)
  • The primary purpose of this study is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD. (mayo.edu)
  • 70%) and poor long-term outcome with an overall survival of only 6 months ( 3 ). (frontiersin.org)
  • however, the overall survival is poor because of local and distant relapses. (springeropen.com)
  • TP53 mutation was associated with poorer overall survival and increased risk of relapse. (ascopost.com)
  • If we look to the head-to-head comparison, the overall survival data are still immature, however [the data] look quite promising," says lead investigator Valentin Goede, a clinical scientist at the University Hospital of Cologne in Germany. (curetoday.com)
  • The trial data also appears to suggest an overall survival benefit with RD. At the four-year follow-up, 59.4 percent of patients receiving continuous RD were alive compared with 51.4 percent receiving the MPT combination, but the difference is not significant, meaning the improvement in survival could be by chance. (curetoday.com)
  • With a median follow-up after HSCT of 39.4 months (range, 1 to 145 months), the probability of overall survival (OS) at 1, 2, and 5 years was 69.6%, 61.1% and 50.3%, respectively, with a median OS of 62 months. (uniba.it)
  • Despite treatment of CMV infection with antiviral drugs, CMV reactivation remains a major problem because it reduces the overall survival of patients after allo-HSCT. (cttjournal.com)
  • The use of prophylactic infusion of selected lymphocytes (CD45RA- fraction, CMV-specific T-lymphocytes) probably can improve the reconstitution of antiviral immunity, reduce the frequency of reactivation and increase overall survival in these categories of patients. (cttjournal.com)
  • High pre-HSCT BAALC / ABL1 copy numbers significantly associated with higher cumulative incidence of relapse and shorter overall survival in univariable and multivariable models. (oncotarget.com)
  • it showed superior progression-free and overall survival with ibrutinib-rituximab compared with FCR, in particular in patients without the IGHV mutation, and lower rates of serious infectious complications with ibrutinib-rituximab. (medscape.com)
  • A systematic review evaluated CHOP or CHOP-like regimens in 2815 patients with PTCL, with a 5-year overall survival (OS) of 38.5 % [ 4 ]. (biomedcentral.com)
  • Endpoints of the study were overall survival (OS) progression-free survival (PFS) transplant-related mortality (TRM) engraftment cumulative incidence of illness and GVHD. (bio-cavagnou.info)
Patients112
  • Less than half of these patients are cured, even with the use of high-dose therapy followed by autologous bone marrow or stem cell rescue. (medscape.com)
  • Estimate the failure-free survival rate in a cohort of relapsed Hodgkin's lymphoma and non-Hodgkin's lymphoma patients after retrieval therapy which includes peripheral blood stem cell transplantation (PBSCT) in patients who achieve a complete remission or partial remission. (knowcancer.com)
  • Estimate the post complete/partial remission failure-free survival rate in these patients. (knowcancer.com)
  • Characterize the time to recovery of normal bone marrow function after transplantation in these patients. (knowcancer.com)
  • OUTLINE: Patients receive 2 courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. (knowcancer.com)
  • Neoepitope specific peptide vaccines targeting the clonal driver mutation H3 K27M have been shown to illicit cytotoxic T-cell and T-helper cell responses in patients with diffuse midline glioma. (wikipedia.org)
  • Survival of patients with SDS who develop myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is poor 10 . (nature.com)
  • Therefore, a central goal in clinical care of SDS patients is to identify incipient leukemic transformation and initiate pre-emptive treatment with allogeneic stem cell transplantation. (nature.com)
  • Current surveillance strategies for patients with SDS and other leukemia predisposition syndromes rely on monitoring hematologic status by serial peripheral blood counts to identify worsening cytopenias and bone marrow examinations to identify morphologic changes or development of clonal chromosomal abnormalities 11 . (nature.com)
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (drugs.com)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis (haplo-PTCY) and unrelated double-unit umbilical cord blood transplantation (dUCBT) are feasible options for treating patients with high-risk acute myelogenous leukemia (AML). (unisr.it)
  • This study compared outcomes after dUCBT and haplo-HCT using peripheral blood stem cells (PBSCs) in adult patients with AML in complete remission (CR) who underwent transplantation in European Society for Blood and Marrow Transplantation (EBMT)-affiliated centers. (unisr.it)
  • Patients receiving in vivo antithymocyte globulin, Campath, or ex vivo T cell depletion were excluded. (unisr.it)
  • peripheral blood and cord blood progenitors were used in 73 (7%) and 88 (9%) patients, respectively. (duke.edu)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • Allogeneic hematopoietic stem cell transplant (aHSCT) patients are well known to be at high risk of vitamin D (vit D) deficiency. (bvsalud.org)
  • This study included patients who presented with symptoms or signs related to dengue infection and who had a complete blood count and dengue investigation performed during September 2019 to May 2020. (bvsalud.org)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
  • Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall response (OR) 3 months later. (frontiersin.org)
  • Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
  • Pegfilgrastim is used to reduce the risk of infection in some cancer patients and to increase your chances of surviving after exposure to high doses of radiation that affect your ability to make blood cells. (drugs.com)
  • Determine the feasibility and efficacy of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, melphalan, and thiotepa followed by allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies. (knowcancer.com)
  • Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients. (knowcancer.com)
  • T cell preparation: Patients and donors undergo apheresis to obtain peripheral blood mononuclear cells (PBMCs), which are expanded in culture. (knowcancer.com)
  • Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo allogeneic PBSC transplantation on day 0. (knowcancer.com)
  • LMB-2 immunotoxin-treated, selectively-depleted donor T cells: Patients receive LMB-2 immunotoxin-treated, selectively-depleted donor T cells IV over 30-60 minutes on approximately day 28. (knowcancer.com)
  • Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
  • After completion of study treatment, patients are followed weekly for 100 days post-transplantation and then periodically for survival. (knowcancer.com)
  • Because there is no effective chemotherapeutic regimen for intrathoracic malignant neurogenic tumor, all three patients received high-dose chemotherapy followed by hematopoietic stem cell transplantation. (springeropen.com)
  • In a study reported in The New England Journal of Medicine , R. Coleman Lindsley, MD, PhD , of Dana-Farber Cancer Institute, and colleagues found that a number of mutations present in patients with myelodysplastic syndromes (MDS) were associated with poorer clinical outcome after allogeneic hematopoietic stem cell transplantation. (ascopost.com)
  • The study involved targeted mutational analysis of samples obtained before stem cell transplant from 1,514 MDS patients enrolled at the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. (ascopost.com)
  • Genetic profiling revealed that molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for MDS may inform prognostic stratification and the selection of conditioning regimen. (ascopost.com)
  • among patients without TP53 mutations, survival was similar among those with therapy-related MDS vs primary MDS (HR = 1.10, P = .37). (ascopost.com)
  • PPM1D mutation vs no mutation was not associated with poorer survival in patients with therapy-related MDS without TP53 mutations (HR = 1.26, P = .39). (ascopost.com)
  • Supportive care for patients with symptomatic Fanconi anemia includes transfusions of packed RBCs that have been leukodepleted (and are not from family members, to avoid sensitization in case of a future transplantation). (medscape.com)
  • A study by MacMillan et al reported that alternative donor hematopoietic cell transplantation had a high success rate in patients with Fanconi anemia who did not have a history of opportunistic infections or transfusions and who underwent conditioning with single fraction total body irradiation 300 cGy, cyclophosphamide, fludarabine, and antithymocyte globulin. (medscape.com)
  • Survival probability in these patients was 94% at 5 years, according to the investigators. (medscape.com)
  • The study, which involved 130 patients, also found that adding fludarabine to conditioning caused three-fold enhancement of hematopoietic cell engraftment. (medscape.com)
  • Although the only therapy that can cure the pancytopenia is stem cell transplantation, androgens, to which approximately 50-75% of patients respond, are used for those in whom transplantation is not an option. (medscape.com)
  • For the 20 OSMS patients, the overall EDSS score decreased significantly after transplantation (P = 0.016), while visual functions had no significant improvement (P = 0.716). (cellsurgicalnetwork.com)
  • Children who develop acute myeloid leukemia (AML) are typically treated with chemotherapy, but more than half of patients eventually relapse and go on to transplantation or second-line therapy. (curetoday.com)
  • A phase 3 study shows Mylotarg (gemtuzumab ozogamicin), when given with standard chemotherapy, decreased the risk of relapse, especially in patients who later undergo a transplantation. (curetoday.com)
  • Since there is a delay in the appearance of the T cells that come from stem cells to get out of the bone marrow and into the blood, we will give patients both gene-modified T cells for a first wave of antitumor activity and gene-modified stem cells which will provide a bridge until the stem cells have produced more T cells. (ca.gov)
  • Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
  • The actuarial event-free survival for these 56 patients at 3 years was 37% and was at least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. (shengsci.com)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • Dr. Steven Suter, assistant professor of oncology in NC State's College of Veterinary Medicine, received three leukophoresis machines donated by the Mayo Clinic in Rochester, Minn. Leukophoresis machines are designed to harvest healthy stem cells from cancer patients. (thepracticesolution.net)
  • Doctors have been treating human patients with bone marrow transplantation for many years, and there have been canine patient transplants performed in a research setting for about 20 years, but it's never been feasible as a standard therapy until now. (thepracticesolution.net)
  • We performed a nationwide registry-based analysis to describe the clinical outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a tyrosine kinase inhibitor (TKI)-based treatment A total of 441 patients were included in the study. (uniba.it)
  • Thirty-eight patients (4.83%) had pathologic findings before transplantation. (slideshare.net)
  • Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide which is usually calculated based on the patient's weight. (slideshare.net)
  • CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. (stembook.org)
  • Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. (stembook.org)
  • We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)
  • In 15 to 20% of patients, plasma cells secrete only Bence Jones protein. (merckmanuals.com)
  • Rarely, patients have no M-protein in blood and urine, although the currently used serum free light chain assay now demonstrates monoclonal light chains in many of these formerly so-called nonsecretory patients. (merckmanuals.com)
  • Cell therapy is a potential new treatment for post MI patients, but the main challenges are : the necessity to preserve immune competency and to gain adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • As such, stem cell therapy cannot be regarded as a valid therapeutic option for patients with cardiovascular disease in the present era of evidenced-based medicine, yet it holds great hope for the future. (escardio.org)
  • Cell therapy is currently emerging as a potential new treatment for post MI patients with the assumption that recolonization of the areas of scarred myocardium with exogenously supplied surrogates or precursors of cardiomyocytes can restore function and ultimately affect clinical outcomes. (escardio.org)
  • Several preliminary reports have demonstrated that local stem cell transplantation in patients with acute myocardial infarction is safe and may lead to improved myocardial function and perfusion. (escardio.org)
  • CMV infection is one of most frequent infectious complications in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). (cttjournal.com)
  • We analyzed cytotoxic T-lymphocytes (CTLs) in peripheral blood of 39 patients on day +30 after allo-HSCT. (cttjournal.com)
  • Figure 1 shows the number of CMV-specific T cells at the day +30 after allo-HSCT in patients with various modes of GVHD prophylaxis. (cttjournal.com)
  • Patients with more "aggressive" GVHD prophylaxis regimens (based on the use of high doses of post-transplant cyclophosphamide, T-cell depletion) have less CMV-specific T cells at +30 days after allo-HSCT. (cttjournal.com)
  • The patients with "aggressive" GVHD prophylaxis are the most likely candidates for cell therapy. (cttjournal.com)
  • The "dot plot" shows the results of the study of CMV-specific T cells in one of the patients with T-depletion at +30 days after HSCT. (cttjournal.com)
  • Advances in the management of the underlying malignancies and support of organ dysfunctions have led to survival gains in patients with life-threatening complications from the malignancy itself, as well as infectious and toxic adverse effects related to the oncological treatments. (springeropen.com)
  • Similarly, because hematologists and oncologists select patients for ICU admission based on the characteristics of the malignancy, the underlying malignancy rarely influences short-term survival after ICU admission. (springeropen.com)
  • Because of the overall increased survival that has been reported in critically ill patients with cancer, we outline an easy-to-use and evidence-based ICU admission triage criteria that may help avoid depriving life support to patients with cancer who can benefit. (springeropen.com)
  • Critically ill cancer patients have lower survival rates compared with patients without comorbidities. (springeropen.com)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment for acute myeloid leukemia patients. (oncotarget.com)
  • We performed absolute quantification of BAALC copy numbers in peripheral blood prior (median 7 days) to HSCT in complete remission (CR) or CR with incomplete peripheral recovery in 82 acute myeloid leukemia patients using digital droplet PCR (ddPCR) technology. (oncotarget.com)
  • Evaluation of pre-HSCT BAALC / ABL1 copy numbers in peripheral blood by ddPCR represents a feasible and rapid way to identify acute myeloid leukemia patients at high risk of early relapse after HSCT. (oncotarget.com)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
  • Successful allogeneic transplantation of patients with suspected prior invasive mold infection. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with extensive disease, respectively. (the-medical-dictionary.com)
  • In patients with limited disease (LD), the CR rate is 16 to 18%, with a median survival of 11.7 to 12.4 months. (the-medical-dictionary.com)
  • Patients with CLL typically have a higher-than-normal white blood cell count, which is determined by a complete blood count (CBC). (medscape.com)
  • A third of these patients subsequently underwent allogeneic hemopoietic stem cell transplantation. (medscape.com)
  • The drug was recently approved by the US Food and Drug Administration for patients with Philadelphia chromosome-negative precursor B-cell ALL who have relapsed or who were refractory to previous treatment. (medscape.com)
  • The study reported by Dr Topp and colleagues enrolled 189 patients with Philadelphia chromosome-negative, primary refractory or relapsed disease (first relapse within 12 months of first remission, relapse within 12 months after allogeneic hemopoietic stem cell transplantation, or no response to or relapse after first salvage therapy or beyond). (medscape.com)
  • It was noted that the ALK-positive ALCL patients did particularly well with CHOEP, with a significant improvement in both event-free survival and OS. (biomedcentral.com)
  • In such procedures, patients undergo successive treatments with cell mobilization agents to cause mobilization of hematopoietic progenitor cells from the bone marrow to the peripheral circulation for harvesting. (justia.com)
  • In many cases, successfully mobilization is not effected in the patient and inadequate numbers of hematopoietic stem cells are harvested from these patients using current methods. (justia.com)
  • All patients can evolve into trisomy 8+ MDS [12], cells, since acquiring adequate samples diagnosed with MDS have a reduced in which 8+ appears to confer a favour- for flow cytometric analysis renders the life expectancy compared with age- able prognosis [13]. (who.int)
  • The essence of MDS is damage of In the current work we examined All our patients were of the high-risk colony-forming units [4], but the defect haematopoietic stem cells of high-risk group and none of them was eligible of the haematopoietic stem cells is not MDS cases for apoptotic and anti-apop- for stem cell transplantation. (who.int)
  • Most patients with BPDCN have skin lesions and simultaneous involvement of the peripheral blood, bone marrow, and lymph nodes. (elsevierpure.com)
  • Most patients with BPDCN have skin lesions and simultaneous involvement of the peripheral blood, bone marrow, and lymph nodes.Methods: A search of PubMed and Medline was conducted for English-written articles relating to BPDCN, CD4+CD56+ hematodermic neoplasm, and blastic natural killer cell lymphoma. (elsevierpure.com)
  • In a multicentre, single-arm, open-label phase 2 study, we enrolled adult patients with Philadelphia-chromosome-negative, primary refractory or relapsed (first relapse within 12 months of first remission, relapse within 12 months after allogeneic haemopoietic stem-cell transplantation [HSCT], or no response to or relapse after first salvage therapy or beyond) leukaemia. (nih.gov)
  • The persistent and widening gap between patients' need for organs and the number available for transplantation has become a major concern to many Member States. (who.int)
  • Even between countries which have similar levels of health resources, patients' access to transplantation also varies. (who.int)
  • Moreover, for patients who have kidney failure, access to transplantation is reduced when funds are spent on other forms of treatment that are less cost-effective. (who.int)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • To describe the psychological suffering developed by patients transplanted with hematopoietic stem cells from a referral service in the state of Rio Grande do Norte. (bvsalud.org)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
  • These infections occur in severely immunocompromised patients, such as persons with AIDS, or patients undergoing extensive treatment, such as cancer treatment or organ transplantation ( 1 - 4 ). (cdc.gov)
  • The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)
HSCT4
  • The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. (mayo.edu)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
Lymphoma12
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • Canine lymphoma is one of the most common types of cancer in dogs, but the survival rate with current treatments is extremely low. (thepracticesolution.net)
  • Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. (u-tokyo-hemat.com)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. (biomedcentral.com)
  • In the nodal T cell lymphomas, the major subtypes are PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and ALK-negative ALCL. (biomedcentral.com)
  • Methods: A search of PubMed and Medline was conducted for English-written articles relating to BPDCN, CD4 + CD56 + hematodermic neoplasm, and blastic natural killer cell lymphoma. (elsevierpure.com)
  • This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
  • Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. (lu.se)
  • Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. (lu.se)
  • Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. (lu.se)
  • Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. (lu.se)
Transplant17
  • Hematopoietic cell transplantation is, to date, the only curative therapy for SCD, but its application is limited by availability of a suitable HLA-matched donor and lack of awareness of the benefits of transplant. (duke.edu)
  • Included in this study are 1000 recipients of HLA-identical sibling transplants performed between 1986 and 2013 and reported to the European Society for Blood and Marrow Transplantation, Eurocord, and the Center for International Blood and Marrow Transplant Research. (duke.edu)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • Related transplant donors must be proven not to have Fanconi anemia in order for a transplantation to succeed. (medscape.com)
  • Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. (stembook.org)
  • Transplant Cell Ther. (stembook.org)
  • Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. (stembook.org)
  • Biol Blood Marrow Transplant. (stembook.org)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Predictors for survival after transplant relapse. (uchicago.edu)
  • This is an important study, and ultimately, I think our goal is to overcome the use of chemotherapy and radiation, which can destroy healthy cells along with malignant ones," commented Catherine Bollard, MD, MBChB, a bone and marrow transplant specialist at George Washington University/Children's National Medical Health System, Washington, DC. (medscape.com)
  • Statistical Analysis This study was designed as a single center non-randomized phase II trial to investigate the feasibility and security of a non-myeloablative conditioning routine plus an unmodified peripheral blood stem cell transplant in individuals with hematologic malignancies who are not candidates for myeloablative conditioning by virtue of age prior organ toxicity or intensity of prior therapy. (bio-cavagnou.info)
Kidney Transplantation2
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • For example, in developing and developed countries alike, kidney transplantation not only yields survival rates and quality-of-life that are far superior to those obtained with other treatments for end-stage renal disease, such as haemodialysis, but is also less costly in the long run. (who.int)
Post-transplantation2
  • Donor/sponsor chimerism was regularly performed every 3 months for the 1st yr post transplantation using short-tandem repeat (STR) amplified by polymerase chain reaction (PCR). (bio-cavagnou.info)
  • Life-threatening infections required vasopressors and/or intubation and included Sobetirome any viral end-organ disease EBV-post-transplantation lymphoproliferative disorder (EBV-PTLD) or infections. (bio-cavagnou.info)
Multiple myeloma5
Graft-versus-3
  • Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. (stembook.org)
  • Reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT) have used alemtuzumab to abrogate the risk of graft-versus-host disease (GVHD). (bio-cavagnou.info)
  • Our hypothesis about a splenic stem cell contributionor maintained survival compared to bone marrow transplants, to PBSCT also derives from the observation that G-CSF mobilizationsalthough graft versus host disease (GVHD) still occurs [1]. (fliphtml5.com)
Remission2
  • Allogeneic hematopoietic stem cell transplantation, particularly when performed during the first remission, may produce durable remissions in selected adults. (elsevierpure.com)
  • The primary endpoint was complete remission (CR) or CR with partial haematological recovery of peripheral blood counts (CRh) within the first two cycles. (nih.gov)
Donors8
  • The survival rate after transplantation from alternative donors is improving, depending on the completeness of the HLA-matching. (medscape.com)
  • Infections following Transplantation of Bone Marrow or Peripheral-Blood Stem Cells from Unrelated Donors. (stembook.org)
  • Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. (uchicago.edu)
  • In addition atovaquone or trimethoprim-sulfamethoxazole was prescribed for prevention of toxoplasmosis infections after transplantation in seropositive individuals or those with seropositive donors. (bio-cavagnou.info)
  • Samples of peripheral blood lymphocytes (PBLs) were obtained from ten normal untreateddonors and 18 normal donors treated with G-CSF. (fliphtml5.com)
  • Interestingly, thiscell transplants (PBSCTs) from donors given granulocyte-colony- immature peripheral phenotype was similar to bone marrow transplantsstimulating-factor (G-CSF) has decreased relapse rates and improved before G-CSF. (fliphtml5.com)
  • For induce splenomegaly in most donors and in rare, severe cases splenicautologous stem cell transplants, the use of autologous PBSCT from rupture [13,14]. (fliphtml5.com)
  • Organ Transplantation.2 These Guiding Principles - whose emphases include voluntary donation, noncommercialization, genetic relation of recipients to donors and a preference for cadavers over living donors as sources - have considerably influenced professional codes, national, state and provincial legislation, and the policies of intergovernmental organizations. (who.int)
Lymphomas5
  • CD19 is a protein expressed on the surface of B-cell-derived ALLs and non-Hodgkin's lymphomas. (medscape.com)
  • The International PTCL project that collected 1314 cases of T/NK-cell lymphomas from 22 institutions worldwide revealed that the most common subtypes worldwide are the nodal T cell lymphomas [ 2 ]. (biomedcentral.com)
  • however, outcomes are poor when PTCL is treated according to strategies established for aggressive B cell lymphomas [ 3 ]. (biomedcentral.com)
  • Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. (astct.org)
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)
Prognostic3
  • Age, stage, and biological features encountered in tumor cells are important prognostic factors and are used for risk stratification and treatment assignment. (medscape.com)
  • For example, neutropenia or autologous bone marrow transplantation (BMT) have less adverse prognostic implications than two decades ago. (springeropen.com)
  • The aim was to identify cellular and cytogenetic markers of prognostic relevance to survival of high-risk MDS cases. (who.int)
High-dose5
Lymphocytes1
  • Recent studies have shown that soluble factors elaborated by human T lymphocytes enhance erythroid burst formation by human peripheral blood null cells. (shengsci.com)
Median4
  • The median age at transplantation was 9 years, and the median follow-up was longer than 5 years. (duke.edu)
  • The median number of CD34+ cells collected was 13.11 x [10.sup.6]/kg. (the-medical-dictionary.com)
  • Response rates in extensive disease (ED) range from 51 to 78%, including a 7 to 13% rate of complete response (CR) and a median survival of 8 to 9 months. (the-medical-dictionary.com)
  • Median survival rates ranged between 12 and 16 months. (elsevierpure.com)
Outcomes2
Haematopoietic stem cells2
  • ABSTRACT This study examined haematopoietic stem cells of 19 high-risk cases of myelodysplastic syndrome (MDS) for apoptotic and anti-apoptotic signals and cellular proliferation and correlated these with clinical and cytogenetic subtypes, particularly trisomy 8. (who.int)
  • 1 This includes human cells for transplantation such as haematopoietic stem cells from bone marrow, peripheral blood or cord blood. (who.int)
Progression-free sur2
  • The confirmed relapse-free survival rate was 62.9% and progression-free survival rate was 83.3% after 91Â months according to Kaplan and Meier survival curves. (cellsurgicalnetwork.com)
  • Updated results announced at the ASH conference found Gazyva significantly delayed progression-free survival over Rituxan (26.7 months versus 15.2 months). (curetoday.com)
Regimen1
  • Successful transplantation of organs and living tissues depends on continued medical follow-up and the patient's compliance with a regimen of immunosuppressive drugs. (who.int)
Granulocyte colony1
Marrow Transplantation5
Disease8
  • Scholars@Duke publication: Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. (duke.edu)
  • Despite advances in supportive therapy to prevent complications of sickle cell disease (SCD), access to care is not universal. (duke.edu)
  • Those with intermediate-risk disease and a matched related donor or with high-risk disease moved on to transplantation. (curetoday.com)
  • Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR. (stembook.org)
  • Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. (uchicago.edu)
  • Leukocytic, hematopoietic cells are important in maintaining the body's defense against disease. (justia.com)
  • The spleen also uniquely contributes toGraft Versus Host Disease (GVHD) complete B cell memory [11]. (fliphtml5.com)
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
Counts4
  • The most common side effects included low white blood cell counts (neutropenia), infusion-related reactions and low blood platelet counts (thrombocytopenia). (curetoday.com)
  • Two-platform method was used to calculate absolute CMV (NLV/TPR)-specific CD3+CD8+ cell counts in peripheral blood. (cttjournal.com)
  • These therapies decrease a patient's white blood cell counts, suppress bone marrow hematopoietic activity, and increase the patient's risk of infection and/or hemorrhage. (justia.com)
  • A total of 11 plasma ex- nisolone daily, with advice to get her blood change sessions were carried out over a counts tested at regular intervals. (who.int)
Cord2
  • Hematopoietic stem cell transplantation (bone marrow, cord blood, or peripheral blood stem cells) may cure aplastic anemia and prevent myelodysplastic syndrome or leukemia. (medscape.com)
  • A short cold panel including a 3-cell antibody screen, autologous control, and type O cord cells was reactive at immediate spin, 15-30 minute incubation at room temperature, and 15-30 minute incubation at 4°C. The patient's antibody screen was negative using the prewarmed technique, and of interest, in view of their brief in vivo survival, all units tested were compatible by prewarmed cross-match. (medscape.com)
Outcome1
  • The excellent outcome of a cohort transplanted over the course of 3 decades confirms the role of HLA-identical sibling transplantation for children and adults with SCD. (duke.edu)
Treatment11
  • Treatment is with tyrosine kinase inhibitors (TKI) such as imatinib , dasatinib , nilotinib , bosutinib , and ponatinib , which significantly improve response and prolong survival. (msdmanuals.com)
  • and six experienced neurological deterioration after transplantation and needed further immunosuppressant treatment. (cellsurgicalnetwork.com)
  • The annual meeting of the American Society of Hematology (ASH) was held in December, bringing thousands of cancer researchers, physicians and industry professionals to New Orleans to report on critical issues in blood cancer treatment, screening, prevention and supportive care. (curetoday.com)
  • A strategy in the treatment of cancer by harnessing the immune system, called adoptive cell therapy, is to use an individual's own immune cells (T cells) and genetically modify them to target them to kill the cancer. (ca.gov)
  • This treatment is called peripheral blood stem cell transplantation. (thepracticesolution.net)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
  • Combination chemotherapy with cisplatin and etoposide (cisplatin-etoposide [PE]) has long been the mainstay of treatment for small cell lung cancer (SCLC). (the-medical-dictionary.com)
  • This review summarizes the currently available approaches for the treatment of PTCL with an emphasis on potential new agents, including the role of stem cell transplantation. (biomedcentral.com)
  • The success of treatment crucially depends on the mobilization of the bone marrow stem cells, the subsequent return of which permits the patient to achieve reconstitution of a functioning hematopoietic system. (justia.com)
  • TheIntroduction later step is unique to splenic function since splenectomy results in similar accumulations of naïve B cells, reduction of memory B cells and Treatment of malignancies with allogeneic peripheral blood stem well-known susceptibilities to select infections [12]. (fliphtml5.com)
  • The Food and Drug Administration approved a treatment that uses gene therapy to treat severe hemophilia A, a rare and sometimes fatal blood disorder. (cdc.gov)
Neoplasm2
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
  • Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. (elsevierpure.com)
Thrombocytopenia1
  • Muscat, from a regional hospital, suffering ted diseases, with varying incidence, con- from anaemia and thrombocytopenia with tracted even after the transfusion of episodes of generalized convulsions and properly tested blood [ 2,3 ]. (who.int)
Clinical6
  • Our emerging clinical data demonstrates that these gene-modified T cells are very active in killing tumor cells initially, but they lose their ability to function within a few weeks. (ca.gov)
  • Preclinical and some small-scaled clinical trials have suggested feasibility and safety of cardiac stem cell therapy. (escardio.org)
  • Various cell types have been tested experimentally for cardiac repair so far, but only those of autologous origin have yet undergone clinical testing due to immune competency. (escardio.org)
  • In experimental and clinical studies unselected mononuclear bone marrow cells as well as specific subpopulations have been used for transplantation. (escardio.org)
  • Enrichment of PBSCT by purification of CD34+stem cells fails to produce superior clinical benefits. (fliphtml5.com)
  • The inferior clinical performance of CD34+-enriched and purified PBSCTs compared tounenriched PBSCTs may be explained by the omission of Hox11+ stem cells. (fliphtml5.com)
Differentiation4
  • One was a solid or isolated growth of oval primitive cells with Schwannian stroma, representative of a neuroblastoma (Figure 1 C). The second was a diffuse growth of large polygonal cells with ganglion cell differentiation and prominent Schwannian stroma, which was regarded as a ganglioneuroma. (springeropen.com)
  • Moreover, it seems that paracrine action of skeletal myoblasts facilitate neighboring cardiomyocytes to maintain their replicative potential and/or stimulate differentiation of native cardiac stem cells (8,9). (escardio.org)
  • Sequential rounds of division and differentiation give rise to an enormous amplification of cell numbers, necessary for the production of mature blood cells. (justia.com)
  • This process of division and differentiation is subject to regulation at many levels to control cell production. (justia.com)
ASCT3
  • Peripheral blood samples were collected for measuring monocytic (M-) MDSCs (CD14 pos HLA-DR low/neg ) and early-stage (E-) MDSCs (Lin neg HLA-DR neg CD33 pos CD11b pos ) before and after ASCT. (biomedcentral.com)
  • Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
  • We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
Oncology1
  • Studies have shown little improvement in survival, although efforts (see below) through the Children's Oncology Group (COG), Paediatric Brain Tumour Consortium (PBTC), and others are underway to explore further the use of chemotherapy and other drugs. (wikipedia.org)
Donor4
  • OUTLINE: This is a dose-escalation study of LMB-2 immunotoxin-treated, selectively-depleted donor T cells. (knowcancer.com)
  • LMB-2 immunotoxin is added to the PBMCs in order to selectively deplete T cells from the donor PBMCs. (knowcancer.com)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • CMV reactivation by CMV pp65 antigenemia assay of peripheral blood was monitored regularly through day time +100 when either the patient or donor was CMV seropositive. (bio-cavagnou.info)
Endothelial progenitor cells3
  • The bone morrow contains several stem cell types including hematopoetic stem cells, endothelial progenitor cells, mesenchymal (stromal) stem cells and multipotent adult progenitor cells. (escardio.org)
  • Human endothelial progenitor cells (hEPCs) are adult stem cells, located in the bone marrow and peripheral blood. (intechopen.com)
  • Different phenotypes and subtypes of endothelial progenitor cells (EPCs), such as early and late EPCs, have been described according to their functionality. (intechopen.com)
Methods4
  • Cell Rep Methods. (u-tokyo-hemat.com)
  • Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. (justia.com)
  • Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. (justia.com)
  • The present invention relates generally to improved methods and pharmaceutical compositions for mobilizing hematopoietic stem and progenitor cell from bone marrow into peripheral blood by administration of at least one inhibitor of a GTPase, such as Rac1 and/or Rac2 GTPase. (justia.com)
Curative1
Engraftment1
  • Repair of scar tissue constitutes a challenge for cardiac stem cell therapy due to lack of adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
Malignant3
  • Chronic myeloid leukemia (CML) occurs when a pluripotent stem cell undergoes malignant transformation and clonal myeloproliferation, leading to a striking overproduction of mature and immature granulocytes. (msdmanuals.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
  • The diagnosis of BPDCN is based on the characteristic cytology and immunophenotype of malignant cells coexpressing CD4, CD56, CD123, blood dendritic cell antigens 2 and 4, and CD2AP markers. (elsevierpure.com)
Myelodysplastic syndrome1
  • 15]. The percentage of bone common of which are trisomy 8, mono- marrow blast cells for estimation of the Myelodysplastic syndrome (MDS) is somy 7 and 5q- [11]. (who.int)
Mononuclear1
  • At least 6.5 x 10(8) [corrected] mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cyropreserved, and returned intravenously following CBV administration. (shengsci.com)
20222
Conditioning1
Progenitor cell3
  • CML ensues when an abnormal pluripotent hematopoietic progenitor cell initiates excessive production of all myeloid lineage cells, primarily in the bone marrow but also in extramedullary sites (eg, spleen, liver). (msdmanuals.com)
  • Enhancement of human erythroid progenitor cell growth by media conditioned by a human t-lymphocyte line. (shengsci.com)
  • The various mature blood cell types are all ultimately derived from a single class of progenitor cell known as hematopoietic stem cells. (justia.com)